The Comparison of Clinical Efficacy and Safety of Meloxicam versus Diclofenac in Korean Patients with Osteoarthritis of the Knee ; Open Multicenter Comparative Randomized Trial.
- Author:
Jung sik SONG
1
;
Yong Beom PARK
;
Soo Kon LEE
;
Hong Joon AHN
;
Yun Woo LEE
;
Chang Keun LEE
;
Jae Hyun KOH
;
Eun Mi KOH
;
Eun Young LEE
;
Choong Ki LEE
Author Information
1. Division of Rheumatology, College of Medicine, Yonsei University, Korea.
- Publication Type:Multicenter Study ; Original Article ; Randomized Controlled Trial
- Keywords:
Osteoarthritis;
Meloxicam;
Diclofenac
- MeSH:
Diclofenac*;
Eating;
Hospitals, University;
Humans;
Incidence;
Knee*;
Osteoarthritis*;
Physical Examination
- From:The Journal of the Korean Rheumatism Association
2000;7(4):333-341
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: To assess the clinical efficacy and safety of meloxicam 7.5mg versus diclofenac 100mg slow release (SR) in the Korean patients with osteoarthritis of the knee. METHODS: Ninety-one patients of four university hospitals in 1999 were randomized to receive once daily oral meloxicam 7.5mg (N=45) or diclofenac 100mg SR (N=46) for 8 weeks. Clinical efficacy was evaluated using 100mm Visual Analogue Scale (VAS) for pain, Lequesne index after 4, 8 weeks of treatment as well as the physician? and patient? global assessment at the end of treatment. Evaluations for clinical safety were performed using the incidence of adverse events, physical examinations, laboratory finding and total ingestion of antacid during the treatment. RESULTS: After 8 weeks of therapy, both groups had significant improvement in 100mm VAS and Lequesne index than baseline although the difference between two groups did not reach statistical significance. The physician? and patient's global assessment were similar in two groups. The incidence of gastrointestinal adverse events was significantly lower in meloxicam group (24.4%) than diclofenac group (50.0%)(p<0.05). CONCLUSION: Meloxicam 7.5mg is comparable to diclofenac 100mg SR in the treatment of Korean patients with osteoarthritis of the knee. Furthermore meloxicam 7.5mg was well tolerated for 8 weeks and has safe advantage of a significantly lower incidence of gastrointestinal adverse events.
